Trial reportCancer research2010
Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis.
Trial report in Cancer research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05062486 (An Open-Label, Randomized, Double Arm, Phase 2 Study to Evaluate the Safety and Efficacy of C and RQC for Preventing Progression in Age-Related Macular Degeneration), which is not on this map. Cited by 307 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Open-Label, Randomized, Double Arm, Phase 2 Study to Evaluate the Safety and Efficacy of C and RQC for Preventing Progression in Age-Related Macular Degeneration
Who cites it
307 citing papers in PubMed, 7 syntheses or guidelines pooled it, 667 citations in OpenAlex.
- The Biochemical Effects of Resveratrol Intake on the Neurobehavioral Aspects of Autism Spectrum Disorders: A Systematic Review.Central nervous system agents in medicinal chemistry · 2026Pooled it
- The effect of resveratrol supplementation on obesity indices: a critical umbrella review of interventional meta-analyses.Eating and weight disorders : EWD · 2025Pooled it
- Consumption of Red Versus White Wine and Cancer Risk: A Meta-Analysis of Observational Studies.Nutrients · 2025Pooled it
- A Systematic Review of the Impact of Resveratrol on Viral Hepatitis and Chronic Viral Hepatitis-related Hepatocellular Carcinoma.Current molecular medicine · 2025Pooled it
- Resveratrol for the Management of Human Health: How Far Have We Come? A Systematic Review of Resveratrol Clinical Trials to Highlight Gaps and Opportunities.International journal of molecular sciences · 2024Pooled it
- A meta-analysis of resveratrol protects against cerebral ischemia/reperfusion injury: Evidence from rats studies and insight into molecular mechanisms.Frontiers in pharmacology · 2022Pooled it
- Resveratrol for adults with type 2 diabetes mellitus.The Cochrane database of systematic reviews · 2020Pooled it
- Trial
- Impact of systemic resveratrol on non-surgical periodontal treatment of smokers: A 12-month randomized clinical trial.Clinical oral investigations · 2025Trial
- Effect of Resveratrol on Serum Levels of Type II Collagen and Aggrecan in Patients with Knee Osteoarthritis: A Pilot Clinical Study.BioMed research international · 2021Trial
- Resveratrol improves motor function in patients with muscular dystrophies: an open-label, single-arm, phase IIa study.Scientific reports · 2020Trial
- Resveratrol as an effective adjuvant therapy in the management of rheumatoid arthritis: a clinical study.Clinical rheumatology · 2018Trial
- Resveratrol Improves Vascular Function and Mitochondrial Number but Not Glucose Metabolism in Older Adults.The journals of gerontology. Series A, Biological sciences and medical sciences · 2017Trial
- Phytocompounds That Target White Adipose Tissue for Weight Loss: A Review Spanning From Ucp1 Induction in Rodents to Human Clinical Trials.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2026Review
- ERα/SIRT1 signaling mediates the metabolic regulatory benefits of pterostilbene.The Journal of biological chemistry · 2026Article
- Targeting Oxidative Stress in Insulin-Resistant Postmenopausal Women: Effects of Resveratrol and Vitamin C on Oxidative Damage and Antioxidant Defenses in a Randomized Clinical Trial.Antioxidants (Basel, Switzerland) · 2026Article
- An In Silico Study of Resveratrol Derivatives as Dual Inhibitors of Cyclooxygenase-2 (COX-2) and 5-Lipoxygenase (5-LOX) in Cancer Therapy.Biotechnology and applied biochemistry · 2026Article
- Oxyresveratrol Suppresses EGF-Induced AKT Phosphorylation and Reduces Cellular Fitness While Promoting Apoptosis in EGFR-Wild-Type Non-Small Cell Lung Cancer Cells Under EGF Stimulation.International journal of molecular sciences · 2026Article
- Potential Role of Polyphenols in Platelet Aggregation and Blood Coagulation.Journal of cardiovascular development and disease · 2026Review
- Resveratrol therapy modulates inflammatory biomarkers and reverses mechanical allodynia in rats subjected to a temporomandibular joint arthritis model.Inflammopharmacology · 2026Article
247 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 2 countries.
Funding
Abstract
Resveratrol, a naturally occurring polyphenol, has cancer chemopreventive properties in preclinical models. It has been shown to downregulate the levels of insulin-like growth factor-1 (IGF-I) in rodents. The purpose of the study was to assess its safety, pharmacokinetics, and effects on circulating levels of IGF-I and IGF-binding protein-3 (IGFBP-3) after repeated dosing. Forty healthy volunteers ingested resveratrol at 0.5, 1.0, 2.5, or 5.0 g daily for 29 days. Levels of resveratrol and its metabolites were measured by high performance liquid chromatography-UV in plasma obtained before and up to 24 hours after a dose between days 21 and 28. IGF-I and IGFBP-3 were measured by ELISA in plasma taken predosing and on day 29. Resveratrol was safe, but the 2.5 and 5 g doses caused mild to moderate gastrointestinal symptoms. Resveratrol-3-O-sulfate, resveratrol-4'-O-glucuronide, and resveratrol-3-O-glucuronide were major plasma metabolites. Maximal plasma levels and areas under the concentration versus time curve for the metabolites dramatically exceeded those for resveratrol, in the case of areas under the concentration versus time curve, by up to 20.3-fold. Compared with predosing values, the ingestion of resveratrol caused a decrease in circulating IGF-I and IGFBP-3 (P<0.04 for both), respectively, in all volunteers. The decrease was most marked at the 2.5 g dose level. The results suggest that repeated administration of high doses of resveratrol generates micromolar concentrations of parent and much higher levels of glucuronide and sulfate conjugates in the plasma. The observed decrease in circulating IGF-I and IGFBP-3 might contribute to cancer chemopreventive activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.